Neurovascular devices company Rapid Medical revealed on Tuesday the receipt of US FDA clearance for the Comaneci device under the new temporary coil embolization assist devices category.
The company added that the Comaneci device, which is the first and only device in a new temporary coil embolization assist devices category, is the first-ever adjustable, fully-visible aneurysm remodelling device. It acts as a temporary bridge used to aid in the coiling processes while minimising the risk of coil protrusion or prolapse.
According to the company, the Comaneci device is the only temporary coiling assist device that does not require parent vessel occlusion during coiling procedure or the need for long-term antiplatelet medication in case of permanent stenting. It is the only non-vessel-occluding temporary intracranial coiling embolization assist device.
To date, the Comaneci have been successfully used in about 3,000 procedures outside the US, concluded the company.
Shoulder Innovations expands I-Series portfolio with launch of InSet 70 Humeral Stem
GSK commits USD30bn to US R&D and manufacturing expansion
ArtPlayer Promotes Elderly Wellbeing with Digital Signage and Streaming Art in Finnish Care Homes
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Elute partners Spartan Medical
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Abbott's Navitor TAVI system granted CE Mark for expanded indication
PharmaResearch names VIVACY as European distribution partner for Rejuran
Airiver medical receives FDA approval for central airway stenosis trial
Talphera reaches enrollment milestone in NEPHRO CRRT pivotal trial
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
Covalon Technologies secures DTC eligibility to expand US investor access
Navamedic ASA secures final approvals for Flexilev in OraFID across Nordic markets